胰腺癌免疫治疗进展

Research progress of immunotherapy for pancreatic carcinoma

胰腺癌预后差,对传统的治疗不敏感,大多数患者一经诊断即为晚期。传统的治疗方法,包括紫杉醇、氟尿嘧啶类药物、吉西他滨等常用的化疗药物并没有为胰腺癌患者带来显著的生存获益。因此,我们目前需要急切的探索在免疫方面治疗胰腺癌的新思路。当前关于胰腺癌免疫治疗的研究方向主要在以下几个方面:免疫检查点抑制剂、疫苗、T细胞治疗、单克隆抗体、细胞因子等。本文将近年来以上方面的研究进展做一回顾总结。

Pancreatic cancer is one of the most lethal malignancies resistant to conventional therapies. Most of the patients initially diagnosed with locally advanced or metastatic disease which has poor prognosis. Despite chemothera-py regimens such as nab - paclitaxel and gemcitabine or 5 - fluorouracil/leucovorin/ oxaliplatin, traditional therapeutic methods offer a modest survival benefit. Therefore, urgent need for exploring new immunotherapies turns to the center stage of treatments for pancreatic cancer treatment. Current researches on pancreatic cancer immunotherapy mainly fo-cus on the following aspects checkpoint inhibitors, vaccines, adoptive T cells therapy , monoclonal antibodies,and cytokines. In this article , we review the available studies concerning multiple aspects of immunotherapy in pancre-atic cancer.